0001104659-20-132155.txt : 20201203 0001104659-20-132155.hdr.sgml : 20201203 20201203214139 ACCESSION NUMBER: 0001104659-20-132155 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20201201 FILED AS OF DATE: 20201203 DATE AS OF CHANGE: 20201203 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Alkon Daniel L. CENTRAL INDEX KEY: 0001686138 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38045 FILM NUMBER: 201368481 MAIL ADDRESS: STREET 1: C/O NEUROTROPE, INE. STREET 2: 205 EAST 42ND STREET - 20TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10017 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Neurotrope, Inc. CENTRAL INDEX KEY: 0001513856 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 463522381 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 1185 AVENUE OF THE AMERICAS STREET 2: 3RD FLOOR CITY: NEW YORK STATE: NY ZIP: 10036 BUSINESS PHONE: (973) 242-0005 MAIL ADDRESS: STREET 1: 1185 AVENUE OF THE AMERICAS STREET 2: 3RD FLOOR CITY: NEW YORK STATE: NY ZIP: 10036 FORMER COMPANY: FORMER CONFORMED NAME: BlueFlash Communications, Inc. DATE OF NAME CHANGE: 20110223 4 1 tm2037705d7_4seq1.xml OWNERSHIP DOCUMENT X0306 4 2020-12-01 0 0001513856 Neurotrope, Inc. NTRP 0001686138 Alkon Daniel L. C/O NEUROTROPE, INC. 1185 AVENUE OF THE AMERICAS, 3RD FLOOR NEW YORK NY 10036 0 1 0 0 See Remarks Common Stock 2020-12-01 4 D 0 29688 D 0 D Stock Option (right to buy) 56.00 2020-12-01 4 D 0 5469 D Common Stock 5469 0 D Stock Option (right to buy) 10.56 2020-12-01 4 D 0 124274 D Common Stock 124274 0 D Stock Option (right to buy) 19.62 2020-12-01 4 D 0 167000 D Common Stock 167000 0 D Stock Option (right to buy) 3.93 2020-12-01 4 D 0 150000 D Common Stock 150000 0 D Stock Option (right to buy) 0.972 2020-12-01 4 D 0 40000 D Common Stock 40000 0 D Pursuant to the terms of the Agreement and Plan of Merger, dated as of May 17, 2020, by and among Petros Pharmaceuticals, Inc. ("Petros"), Neurotrope, Inc. ("Neurotrope"), PM Merger Sub 1, LLC, PN Merger Sub 2, Inc. and Metuchen Pharmaceuticals LLC, as amended, (the "Merger Agreement") the common stock was disposed of as follows: the reporting person received one (1) share of Petros Common Stock for every five (5) shares of Neurotrope common stock held. Pursuant to the terms of the Merger Agreement, the stock options were disposed of as follows: the reporting person received an option to purchase one (1) share of Petros Common Stock for every option to purchase five (5) shares of Neurotrope common stock held. President, Chief Scientific Officer /s/ Robert Weinstein, Attorney-in-Fact 2020-12-03